These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 1415145

  • 21. Temporal changes in risk factors associated with HIV seroconversion among injection drug users in eastern central Canada.
    Roy E, Richer I, Morissette C, Leclerc P, Parent R, Claessens C, Blanchette C, Alary M.
    AIDS; 2011 Sep 24; 25(15):1897-903. PubMed ID: 21785319
    [Abstract] [Full Text] [Related]

  • 22. An analysis of respondent-driven sampling with injecting drug users in a high HIV prevalent state of India.
    Phukan SK, Medhi GK, Mahanta J, Adhikary R, Thongamba G, Paranjape RS, Akoijam BS.
    Harm Reduct J; 2017 Jul 03; 14(1):41. PubMed ID: 28673303
    [Abstract] [Full Text] [Related]

  • 23. Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users.
    Williams AB, McNelly EA, Williams AE, D'Aquila RT.
    AIDS Care; 1992 Jul 03; 4(1):35-41. PubMed ID: 1314099
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
    Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, Sargent PL.
    Addiction; 2006 Oct 03; 101(10):1499-508. PubMed ID: 16968352
    [Abstract] [Full Text] [Related]

  • 28. Differences in the incidence of hepatitis B and human immunodeficiency virus infections among injecting drug users.
    Levine OS, Vlahov D, Brookmeyer R, Cohn S, Nelson KE.
    J Infect Dis; 1996 Mar 03; 173(3):579-83. PubMed ID: 8627020
    [Abstract] [Full Text] [Related]

  • 29. Continuing injecting risk behaviour: results from the Amsterdam Cohort Study of drug users.
    Van Ameijden EJ, Langendam MW, Notenboom J, Coutinho RA.
    Addiction; 1999 Jul 03; 94(7):1051-61. PubMed ID: 10707443
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.
    van den Berg CH, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, Coutinho RA, Wolthers KC, Prins M.
    Eur J Epidemiol; 2007 Jul 03; 22(3):183-93. PubMed ID: 17334821
    [Abstract] [Full Text] [Related]

  • 32. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
    Wand H, Spiegelman D, Law M, Jalaludin B, Kaldor J, Maher L.
    Addiction; 2009 Dec 03; 104(12):2049-56. PubMed ID: 19804463
    [Abstract] [Full Text] [Related]

  • 33. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
    de Vos AS, van der Helm JJ, Matser A, Prins M, Kretzschmar ME.
    Addiction; 2013 Jun 03; 108(6):1070-81. PubMed ID: 23347124
    [Abstract] [Full Text] [Related]

  • 34. Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study.
    Liu Y, Liu Y, Zou X, Chen W, Ling L.
    BMJ Open; 2017 Jul 13; 7(7):e015524. PubMed ID: 28710214
    [Abstract] [Full Text] [Related]

  • 35. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands.
    van de Laar TJ, Langendam MW, Bruisten SM, Welp EA, Verhaest I, van Ameijden EJ, Coutinho RA, Prins M.
    J Med Virol; 2005 Dec 13; 77(4):509-18. PubMed ID: 16254983
    [Abstract] [Full Text] [Related]

  • 36. A case-control study of HIV infection among incarcerated female drug users: impact of sharing needles and having drug-using sexual partners.
    Peng EY, Yeh CY, Cheng SH, Morisky DE, Lan YC, Chen YM, Lyu SY, Malow RM.
    J Formos Med Assoc; 2011 Jul 13; 110(7):446-53. PubMed ID: 21742248
    [Abstract] [Full Text] [Related]

  • 37. Risk factors for HIV-1 seroconversion among injection drug users: a case-control study.
    Chitwood DD, Griffin DK, Comerford M, Page JB, Trapido EJ, Lai S, McCoy CB.
    Am J Public Health; 1995 Nov 13; 85(11):1538-42. PubMed ID: 7485667
    [Abstract] [Full Text] [Related]

  • 38. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
    Chetwynd J, Brunton C, Blank M, Plumridge E, Baldwin D.
    N Z Med J; 1995 Sep 08; 108(1007):364-6. PubMed ID: 7566775
    [Abstract] [Full Text] [Related]

  • 39. AIDS risk reduction and reduced HIV seroconversion among injection drug users in Bangkok.
    Des Jarlais DC, Choopanya K, Vanichseni S, Plangsringarm K, Sonchai W, Carballo M, Friedmann P, Friedman SR.
    Am J Public Health; 1994 Mar 08; 84(3):452-5. PubMed ID: 8129064
    [Abstract] [Full Text] [Related]

  • 40. Maximum impact of HIV prevention measures targeted at injecting drug users.
    van Ameijden EJ, Coutinho RA.
    AIDS; 1998 Apr 16; 12(6):625-33. PubMed ID: 9583603
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.